| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50 - 1/200 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | Ki-1; D1S166E,TNFRSF8 |
| Entrez GeneID | 943 |
| clone | 1B1A4G2 |
| WB Predicted band size | 63.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Purified recombinant fragment of human CD30 (AA: 416-595) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD30抗体的3篇关键文献及其摘要：
---
1. **文献名称**: *Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas*
**作者**: Younes A, et al.
**摘要**: 该研究报道了抗体药物偶联物Brentuximab Vedotin在复发/难治性CD30阳性淋巴瘤(如霍奇金淋巴瘤和间变性大细胞淋巴瘤)中的疗效。临床试验显示，患者总反应率(ORR)达75%，且药物通过靶向CD30并释放细胞毒素MMAE发挥作用，安全性可控。
---
2. **文献名称**: *CD30-Directed Antibody-Drug Conjugates and Cellular Therapies*
**作者**: Senter PD, et al.
**摘要**: 文章综述了CD30抗体药物偶联物(ADC)的设计与机制，强调其通过单克隆抗体精准递送化疗药物至肿瘤细胞，减少全身毒性。同时探讨了CD30在T细胞淋巴瘤中的生物学意义及未来联合治疗潜力。
---
3. **文献名称**: *Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma*
**作者**: Pro B, et al.
**摘要**: 该II期临床试验评估了Brentuximab Vedotin在复发/难治性霍奇金淋巴瘤患者中的效果，结果显示34%的完全缓解率和40%的部分缓解率，中位缓解持续时间为20个月，证实其作为单药治疗的显著临床价值。
---
以上文献均发表于高影响力期刊(如NEJM、JCO)，涵盖药物机制、关键临床试验及治疗策略，是CD30抗体研究领域的基石性工作。
CD30. a member of the tumor necrosis factor (TNF) receptor superfamily, is a transmembrane glycoprotein initially identified as a marker for activated lymphocytes. It plays roles in regulating cell proliferation, apoptosis, and immune response modulation. While minimally expressed in healthy tissues, CD30 is highly upregulated in certain lymphoproliferative disorders, notably classical Hodgkin lymphoma (cHL) and anaplastic large-cell lymphoma (ALCL), making it a promising therapeutic target.
CD30-targeted antibodies emerged as a breakthrough in hematologic oncology. Brentuximab vedotin, an antibody-drug conjugate (ADC), combines an anti-CD30 monoclonal antibody with a cytotoxic payload (monomethyl auristatin E). Approved in 2011. it revolutionized treatment for relapsed/refractory cHL and ALCL by selectively delivering chemotherapy to CD30-expressing cells, improving survival while reducing systemic toxicity. Naked anti-CD30 antibodies (e.g., iratumumab) showed limited efficacy alone but are explored in combination therapies.
Research continues to expand CD30 antibody applications, including bispecific antibodies, CAR-T cell therapies, and immune checkpoint inhibitor combinations. Challenges remain in addressing heterogeneous CD30 expression in tumors and optimizing therapeutic indices. Nonetheless, CD30 antibodies exemplify successful translational oncology, bridging molecular biology insights to clinically impactful targeted therapies.
×
